Annu Rev Physiol 76: 535-559, 2014
Secondary endpoints included the proportion of patients who achieved 10-15% reduction in weight and changes in metabolic syndrome parameters (waist circumference, HbA 1c , and blood pressure)
A single medication that addresses the reward dysregulation underlying both could simplify treatment, improve compliance (patients are motivated by visible weight loss), and reduce the sense of being pulled in multiple directions that so many patients describe
Ive been on GLPs
Semaglutide can reduce your preference for high-fat and high-sugar foods, which are typically more palatable and rewarding, by modulating the GLP-1 receptors in the brain, which are involved in regulating reward and pleasure
Its a specialist approach that views the patients health as an integrated system rather than a collection of isolated symptoms